



NDA 022127

**NOTIFICATION OF
NON-COMPLIANCE WITH PREA**

Genzyme Corporation
Attention: Melanie Govignon
Principal Associate, Regulatory Affairs
153 Second Avenue
Waltham, MA 02451

Dear Ms. Govignon:

Please refer to your New Drug Application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (the Act) for Renvela (sevelamer carbonate) 800 mg Tablets, which was approved on October 19, 2007.

The Agency has determined that you have failed to meet the requirements of the Pediatric Research Equity Act (PREA) for this application because you have not yet submitted your pediatric assessment, which was deferred until October 20, 2009. We note that you requested a deferral extension on December 5, 2012, however, we have determined that your request does not qualify for an extension.

Under the provisions of title V, section 505, of the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA), you must respond in writing within forty-five calendar days of the date of this letter. Your response should include the reason(s) for the delayed pediatric assessment and a date by which you expect to submit the assessment. You may also include a request for a deferral extension, if applicable. In accordance with FDASIA, FDA will post this letter and your response on the website located at <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm343203.htm> with redactions for any trade secrets and confidential commercial information 60 calendar days from the date of this letter.

Please identify your response to this letter as a “**RESPONSE TO PREA NON-COMPLIANCE LETTER.**” To facilitate our review, submit this information to your NDA with a cross-reference letter to the IND to which your protocol has been submitted. In addition, send a copy of the cover letter to CDER’s Pediatric and Maternal Health Staff.

If you have any questions, call Michael Monteleone, Regulatory Project Manager, at (301) 796-1952.

Sincerely,

{See appended electronic signature page}

Norman Stockbridge, M.D., Ph.D.
Director
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NORMAN L STOCKBRIDGE
04/11/2013